Clinical trial

A Study of Paliperidone Palmitate 6-Month Formulation

NCT03345342

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-11-20

PhasePHASE3

Study timeline

Study start (actual)2017-11-20Date precision: day

Registry last updated2025-04-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

PP6MDRUG

PP3M 350 mg eq.DRUG

PP3M 525 mg eq.DRUG

PP1MDRUG

PlaceboOTHER

Sponsors & collaborators

Janssen Research & Development, LLClead sponsor

Mapped research locations

Saint PetersburgRussia4 PragueCzechia3 São PauloBrazil3 MonterreyMexico3 MiamiFlorida, United States2 BarcelonaSpain2 TaipeiTaiwan2 MoscowRussia2 SofiaBulgaria2 AnkaraTurkey (Türkiye)2 BialystokPoland2 Hong KongHong Kong2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03345342 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.